Skip to main content

$3.44 0.04 (1.18%)

High

$3.45

Low

$3.39

Trades

1,017

Turnover

$1,031,103

Volume

301,613
30 June 2023 at 4:10pm
Register to track ACL and receive email alerts.

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. The company was incorporated in 2020 and is headquartered in Clayton, Australia.

Expand Company Description

Market Cap (10-Oct)

$762,932,544 (281st)

Close (30-Jun)

$3.44

Volume (30-Jun)

301,613

Shortsold (23-Sep)

1,789,091 (0.89%) (227th)

52w High

$3.84

52w Low

$2.08

P/E

12.24

EPS

0.12
Subject
ACL Ann: HLS: Directors' Statement re Takeover

ACL Ann: Response to Healius' Target's Statement

ACL Ann: Second Supplementary Bidder's Statement

ACL Ann: Takeover offer - receipt of Target's Statement

ACL Ann: HLS: Lodgement of Target's Statement

ACL Ann: Completion of dispatch of replacement bidder's statement

ACL Ann: Commencement of dispatch of replacement bidder's statement

ACL Ann: Notice of EGM

ACL Ann: TOV: HLS Panel Declines to Conduct Proceedings

ACL Ann: ASX announcement - Replacement Bidder's Statement

ACL Ann: Replacement Bidder's Statement

ACL Ann: First Supplementary Bidder's Statement

ACL Ann: Change in substantial holding

ACL Ann: Change in substantial holding

ACL Ann: TOV: HLS Panel Receives Application

ACL Ann: Update - Dividend/Distribution - ACL

ACL Ann: Becoming a substantial holder

ACL Ann: Suspension of DRP

ACL Ann: HLS: Directors' Statement re Takeover

ACL Ann: Proposed issue of securities - ACL

ACL Ann: Becoming a substantial holder for HLS

ACL Ann: People to whom information is to be sent

ACL Ann: HLS: Off-market takeover bid from ACL

ACL Ann: Investor Webinar - Takeover Offer for Healius

ACL Ann: Investor Presentation - Takeover Offer for Healius

ACL Ann: Bidder's Statement in relation to Takeover Offer for Healius

ACL Ann: Takeover Offer for Healius Limited

ACL Ann: Notification regarding unquoted securities - ACL

ACL Ann: Change of Director's Interest Notice

ACL Ann: Notification regarding unquoted securities - ACL

ACL Ann: Notification of cessation of securities - ACL

ACL Ann: Ceasing to be a substantial holder

ACL Ann: Dividend/Distribution - ACL

ACL Ann: 1H23 results investor presentation

ACL Ann: Appendix 4D and 1H23 financial reports

ACL Ann: 1H23 Financial Results release details

ACL Ann: Release of Shares from Voluntary Escrow

ACL Ann: Medlab Cyber Incident Update

ACL Ann: Ceasing to be a substantial holder

ACL Ann: Becoming a substantial holder

ACL Ann: Medlab Pathology Cyber Incident

ACL Ann: 2022 AGM - Results of Meeting

ACL Ann: 2022 AGM - addresses to shareholders

ACL Ann: Change of Director's Interest Notice

ACL Ann: Director Appointment/Resignation

ACL Ann: Change of Director's Interest Notice

ACL Ann: Change of Director's Interest Notice

ACL Ann: Ceasing to be a substantial shareholder

ACL Ann: 2022 Annual Report and Corporate Governance Statement

ACL Ann: Appendix 4G

Register to track ACL and receive email alerts.